Kangxinuo Bio: Recombination of New Coronary Vaccine Delivered for New Drug Clinical Trial Pre-review Application
Sauna Night News On March 17, Kang Xinuo Biological Co., Ltd. announced that the company and the Institute of Biological Engineering of the Institute of Military Medical Sciences of the Academy of Military Sciences (“Joint Developer”) are jointly developing a recombinant new coronavirus vaccine (adenovirus vector)) (“Ad5-nCoV”), the vaccine is implanted using genetic engineering methods, using replication-deficient human adenovirus type 5 as a vector, can express the new coronavirus S antigen, and is intended to prevent diseases caused by new coronavirus infection.The joint developer has submitted an application for the pre-review of Ad5-nCoV’s new drug clinical trials to the regulatory agency, and is currently submitting follow-up technical data as required.The joint developer has already begun preparations for clinical trials and alternative pre-recruitment.Article 18A of the Securities Listing Rules of The Stock Exchange of Hong Kong Limited.The warning statement stipulated in Article 05: The safety and effectiveness of Ad5-nCoV must be confirmed by clinical research. We cannot guarantee that we will be able to successfully develop or sell Ad5-nCoV.Shareholders and potential investors of the company should exercise caution when dealing in the shares of the company.Editor Wang Jinyu